← Eichor
Study identifier: NCT07545473 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Retinal Hyperspectral Imaging in Neurodegenerative Diseases

Condition: Dementia · Neurodegenerative Diseases · Alzheimer Disease  ·  Sponsor: Center for Eye Research Australia

PhaseNA
Planned participants930
Who can joinAll sexes, 30 Years to no upper limit
Healthy volunteersYes

About this study

Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides a wealth of information about the retinal structure. Our group has developed evidence supporting a role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. We are undertaking further studies to establish the role of this method in the assessment of people with dementia, or those at risk of Alzheimer's disease. In addition, we wish to test whether the approach may have value in other forms of dementia or neurodegenerative disease such as Parkinson's disease, Lewy-Body dementia or vascular dementia.

This description comes directly from the study's public registry record.

Talk to the study team

Darvy Dang  ·  +61 3 9959 0102  ·  darvy.dang@unimelb.edu.au

Always discuss trial participation with your own doctor first.

Locations (1)

The Centre for Eye Research AustraliaMelbourne, Victoria, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07545473